Interleukin-6 autoantibodies are involved in the pathogenesis of a subset of type 2 diabetes.
暂无分享,去创建一个
T. Hansen | O. Pedersen | A. Steensberg | B. Pedersen | A. Albrechtsen | A. Thomsen | K. Fosgerau | M. Hansen | P. Galle | L. Larsen | C. D. L. Rieper | T. Hansen | Oluf Pedersen | Pia Galle | Adam Steensberg
[1] J. Pickup,et al. NIDDM as a disease of the innate immune system: association of acute-phase reactants and interleukin-6 with metabolic syndrome X , 1997, Diabetologia.
[2] J. Casanova,et al. Recurrent Staphylococcal Cellulitis and Subcutaneous Abscesses in a Child with Autoantibodies against IL-61 , 2008, The Journal of Immunology.
[3] M. Svenson,et al. Transfusion‐related inhibition of cytokines (TRICK). Experimental transfer of neutralizing autoantibodies to interleukin‐6 by plasma transfusions , 2007, Vox sanguinis.
[4] B. Trapnell,et al. GM-CSF autoantibodies and neutrophil dysfunction in pulmonary alveolar proteinosis. , 2007, The New England journal of medicine.
[5] B. Pedersen,et al. Plasma levels of interleukin‐6 and C‐reactive protein are associated with physical inactivity independent of obesity , 2006, Scandinavian journal of medicine & science in sports.
[6] Bruce M. Spiegelman,et al. Adipocytes as regulators of energy balance and glucose homeostasis , 2006, Nature.
[7] T. Kishimoto,et al. Interleukin 6: from bench to bedside , 2006, Nature Clinical Practice Rheumatology.
[8] J. Scheller,et al. Interleukin‐6 biology is coordinated by membrane‐bound and soluble receptors: role in inflammation and cancer , 2006, Journal of leukocyte biology.
[9] C. Fielding,et al. Functional characterization of a soluble gp130 isoform and its therapeutic capacity in an experimental model of inflammatory arthritis. , 2006, Arthritis and rheumatism.
[10] P. J. Larsen,et al. PYY(3-36) reduces food intake and body weight and improves insulin sensitivity in rodent models of diet-induced obesity. , 2006, American journal of physiology. Regulatory, integrative and comparative physiology.
[11] S. Akira,et al. Role of hepatic STAT3 in brain-insulin action on hepatic glucose production. , 2006, Cell metabolism.
[12] Smita Y. Patel,et al. Anti-IFN-γ Autoantibodies in Disseminated Nontuberculous Mycobacterial Infections , 2005, The Journal of Immunology.
[13] D. Relman,et al. Acquired predisposition to mycobacterial disease due to autoantibodies to IFN-gamma. , 2005, The Journal of clinical investigation.
[14] R. Mooney,et al. Interleukin-6 depletion selectively improves hepatic insulin action in obesity. , 2005, Endocrinology.
[15] T. Hansen,et al. Genetics of common forms of glycaemia with pathological impact on vascular biology: are we on the right track? , 2005, Current molecular medicine.
[16] S. Shoelson,et al. Local and systemic insulin resistance resulting from hepatic activation of IKK-β and NF-κB , 2005, Nature Medicine.
[17] Smita Y. Patel,et al. Anti-IFN-gamma autoantibodies in disseminated nontuberculous mycobacterial infections. , 2005, Journal of immunology.
[18] S. Shoelson,et al. Local and systemic insulin resistance resulting from hepatic activation of IKK-beta and NF-kappaB. , 2005, Nature medicine.
[19] K. Bendtzen,et al. High levels of neutralizing IL‐6 autoantibodies in 0.1% of apparently healthy blood donors , 2004, European journal of immunology.
[20] B. Pedersen,et al. Exercise normalises overexpression of TNF-α in knockout mice , 2004 .
[21] B. Pedersen,et al. AMPK activity is diminished in tissues of IL-6 knockout mice: the effect of exercise. , 2004, Biochemical and biophysical research communications.
[22] P. Kern,et al. Lipid and carbohydrate metabolism in mice with a targeted mutation in the IL-6 gene: absence of development of age-related obesity. , 2004, American journal of physiology. Endocrinology and metabolism.
[23] G. Bergström,et al. Reduced exercise endurance in interleukin-6-deficient mice. , 2004, Endocrinology.
[24] U. Göbel,et al. Naturally occurring anti-IFN-gamma autoantibody and severe infections with Mycobacterium cheloneae and Burkholderia cocovenenans. , 2004, Blood.
[25] Y. Kido,et al. Role of STAT-3 in regulation of hepatic gluconeogenic genes and carbohydrate metabolism in vivo , 2004, Nature Medicine.
[26] L. Hougs,et al. Knocking out IL‐6 by vaccination , 2004, European journal of immunology.
[27] B. Pedersen,et al. Exercise normalises overexpression of TNF-alpha in knockout mice. , 2004, Biochemical and biophysical research communications.
[28] T. Zimmers,et al. Chronic exposure to interleukin-6 causes hepatic insulin resistance in mice. , 2003, Diabetes.
[29] T. Kishimoto,et al. Toxicity, pharmacokinetics, and dose-finding study of repetitive treatment with the humanized anti-interleukin 6 receptor antibody MRA in rheumatoid arthritis. Phase I/II clinical study. , 2003, The Journal of rheumatology.
[30] K. Kallen. The role of transsignalling via the agonistic soluble IL-6 receptor in human diseases. , 2002, Biochimica et biophysica acta.
[31] C. Ohlsson,et al. Interleukin-6-deficient mice develop mature-onset obesity , 2002, Nature Medicine.
[32] Lernmark A. Autoimmune diseases: are markers ready for prediction? , 2001, The Journal of clinical investigation.
[33] K. Bendtzen,et al. High-avidity autoantibodies to cytokines. , 1998, Immunology today.
[34] K. Bendtzen,et al. Antibody to granulocyte-macrophage colony-stimulating factor is a dominant anti-cytokine activity in human IgG preparations. , 1998, Blood.
[35] P. Lardelli,et al. Detection of anti-interferon-gamma autoantibodies in subjects infected by Mycobacterium tuberculosis. , 1998, The international journal of tuberculosis and lung disease : the official journal of the International Union against Tuberculosis and Lung Disease.
[36] K. Bendtzen,et al. Increased In Vivo Antibody Activity Against Interferon α, Interleukin-1α, and Interleukin-6 After High-Dose Ig Therapy , 1997 .
[37] K. Bendtzen,et al. Increased in vivo antibody activity against interferon alpha, interleukin-1alpha, and interleukin-6 after high-dose Ig therapy. , 1997, Blood.
[38] T. Kishimoto,et al. Gp130 and the interleukin-6 family of cytokines. , 1997, Annual review of immunology.
[39] F. Brombacher,et al. Pleiotropic Defects of IL‐6—deficient Mice Including Early Hematopoiesis, T and B Cell Function, and Acute Phase Responses , 1995, Annals of the New York Academy of Sciences.
[40] K. Bendtzen,et al. High avidity IFN-neutralizing antibodies in pharmaceutically prepared human IgG. , 1995, The Journal of clinical investigation.
[41] K. Yasukawa,et al. Influence of interleukin‐6 (IL‐6) autoantibodies on IL‐6 binding to cellular receptors , 1995, European journal of immunology.
[42] R. Zinkernagel,et al. Impaired immune and acute-phase responses in interleukin-6-deficient mice , 1994, Nature.
[43] K. Bendtzen,et al. Binding of cytokines to pharmaceutically prepared human immunoglobulin. , 1993, The Journal of clinical investigation.
[44] K. Bendtzen,et al. High-affinity IgG autoantibodies to IL-6 in sera of normal individuals are competitive inhibitors of IL-6 in vitro. , 1993, Cytokine.
[45] K. Bendtzen,et al. Anti‐Interleukin‐6 Antibodies in Normal Human Serum , 1991, Scandinavian journal of immunology.